Projects per year
Abstract
YD holds patents and licensing agreements related to the use of RNAs for diagnostic and therapeutic purposes (WO2018229046, licensed to Firalis SA, protecting the use of lncRNAs in the FIMICS panel used for RNAseq in the present paper; other patents and licenses are not related to the present work). YD is Scientific Advisory Board member of Firalis SA. PF is the founder and CEO of Pharmahungary Group, a group of R&D companies. LB declares to have acted as a SAB member of Sanofi, Ionnis, MSD and NovoNordisk; to have received speaker fees from Sanofi, Bayer and AB‐Biotics SA and to have founded the spin‐off Ivastatin Therapeutics S.L. (all unrelated to this work). TP declares to have received speaker fees from AB‐Biotics SA and to be a co‐founder of the Spin‐off Ivastatin Therapeutics SL (all unrelated to this work). MS received funding from Pfizer Inc. and from Owkin for projects not related to this research. HF is the founder and owner of Firalis SA, a company commercialising the FIMICS panel. He holds patents and licenses for the use of RNAs as biomarkers and therapeutic targets. All other authors declare no competing interests.
Original language | English |
---|---|
Journal | Clinical and Translational Medicine |
Volume | 14 |
Issue number | 10 |
Early online date | 6 Oct 2024 |
DOIs | |
Publication status | Published - 14 Oct 2024 |
Fingerprint
Dive into the research topics of 'Prediction of COVID‐19 severity using machine learning'. Together they form a unique fingerprint.Projects
- 1 Finished
-
COVIRNA: A diagnostic test to improve surveillance and care of COVID-19 patients
1/11/20 → 30/04/23
Project: Research